These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

157 related articles for article (PubMed ID: 3718805)

  • 21. Oxidative polymorphism of debrisoquine in Parkinson's disease.
    Benitez J; Ladero JM; Jimenez-Jimenez FJ; Martinez C; Puerto AM; Valdivielso MJ; Llerena A; Cobaleda J; Muñoz JJ
    J Neurol Neurosurg Psychiatry; 1990 Apr; 53(4):289-92. PubMed ID: 2341841
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Timolol metabolism and debrisoquine oxidation polymorphism: a population study.
    Lennard MS; Lewis RV; Brawn LA; Tucker GT; Ramsay LE; Jackson PR; Woods HF
    Br J Clin Pharmacol; 1989 Apr; 27(4):429-34. PubMed ID: 2719899
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Metoprolol metabolism and debrisoquine oxidation polymorphism--population and family studies.
    McGourty JC; Silas JH; Lennard MS; Tucker GT; Woods HF
    Br J Clin Pharmacol; 1985 Dec; 20(6):555-66. PubMed ID: 2868742
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Pharmacogenetic covariation of defective N-oxidation of sparteine and 4-hydroxylation of debrisoquine.
    Bertilsson L; Dengler HJ; Eichelbaum M; Schulz HU
    Eur J Clin Pharmacol; 1980 Feb; 17(2):153-5. PubMed ID: 7371707
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Codeine O-demethylation co-segregates with polymorphic debrisoquine hydroxylation.
    Yue QY; Svensson JO; Alm C; Sjöqvist F; Säwe J
    Br J Clin Pharmacol; 1989 Dec; 28(6):639-45. PubMed ID: 2611086
    [TBL] [Abstract][Full Text] [Related]  

  • 26. The genetic control of sparteine and debrisoquine metabolism in man with new methods of analysing bimodal distributions.
    Evans DA; Harmer D; Downham DY; Whibley EJ; Idle JR; Ritchie J; Smith RL
    J Med Genet; 1983 Oct; 20(5):321-9. PubMed ID: 6644761
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Ifosfamide plasma clearance in relation to polymorphic debrisoquine oxidation.
    Philip PA; Lewis LD; James CA; Rogers HJ
    Cancer Chemother Pharmacol; 1988; 22(4):321-4. PubMed ID: 3168145
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Pharmacogenetics and drug metabolism: an Irish perspective.
    Holland P; Barry M; Feely J
    Ir J Med Sci; 1991 Feb; 160(2):54-6. PubMed ID: 1917424
    [TBL] [Abstract][Full Text] [Related]  

  • 29. A population and familial study of the defective alicyclic hydroxylation of debrisoquine among Egyptians.
    Mahgoub A; Idle JR; Smith RL
    Xenobiotica; 1979 Jan; 9(1):51-6. PubMed ID: 760321
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Metabolism of paracetamol and phenacetin in relation to debrisoquine oxidation phenotype.
    Veronese ME; McLean S
    Eur J Clin Pharmacol; 1991; 40(6):547-52. PubMed ID: 1884734
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Lack of relationship between debrisoquine oxidation phenotype and the pharmacokinetics and first dose effect of prazosin.
    Lennard MS; McGourty JC; Silas JH
    Br J Clin Pharmacol; 1988 Feb; 25(2):276-8. PubMed ID: 3358891
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Lack of congruence of S-carboxymethyl-L-cysteine sulphoxidation and debrisoquine 4-hydroxylation in a Caucasian population.
    Haley CS; Waring RH; Mitchell SC; Shah RR; Idle JR; Smith RL
    Xenobiotica; 1985 May; 15(5):445-50. PubMed ID: 4036168
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Diurnal effects on debrisoquine hydroxylation phenotyping.
    Lee EJ
    Eur J Clin Pharmacol; 1988; 35(4):441-2. PubMed ID: 3197754
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Non-correlation between debrisoquine and metoprolol polymorphisms in the Venda.
    Sommers DK; Moncrieff J; Avenant J
    Hum Toxicol; 1989 Sep; 8(5):365-8. PubMed ID: 2807305
    [TBL] [Abstract][Full Text] [Related]  

  • 35. N-acetylation and debrisoquine hydroxylation polymorphisms in patients with Gilbert's syndrome.
    Siegmund W; Fengler JD; Franke G; Zschiesche M; Eike O; Eike E; Meisel P; Wulkow R
    Br J Clin Pharmacol; 1991 Oct; 32(4):467-72. PubMed ID: 1958441
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Prediction of phenotype for acetylation and for debrisoquine hydroxylation by DNA-tests in healthy human volunteers.
    Graf T; Broly F; Hoffmann F; Probst M; Meyer UA; Howald H
    Eur J Clin Pharmacol; 1992; 43(4):399-403. PubMed ID: 1451720
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Steady-state concentrations of imipramine and its metabolites in relation to the sparteine/debrisoquine polymorphism.
    Brøsen K; Klysner R; Gram LF; Otton SV; Bech P; Bertilsson L
    Eur J Clin Pharmacol; 1986; 30(6):679-84. PubMed ID: 3533565
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Quinidine and the identification of drugs whose elimination is impaired in subjects classified as poor metabolizers of debrisoquine.
    Speirs CJ; Murray S; Boobis AR; Seddon CE; Davies DS
    Br J Clin Pharmacol; 1986 Dec; 22(6):739-43. PubMed ID: 3567021
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Extensive metabolizers of debrisoquine become poor metabolizers during quinidine treatment.
    Brøsen K; Gram LF; Haghfelt T; Bertilsson L
    Pharmacol Toxicol; 1987 Apr; 60(4):312-4. PubMed ID: 3588528
    [TBL] [Abstract][Full Text] [Related]  

  • 40. The metabolism of debrisoquine in man: (1) regioselectivity of hydroxylation and (2) aberrant oxidative metabolism in two sibling patients with carbimazole-induced agranulocytosis.
    Ritchie JC; Crothers MJ; Shah RR; Idle JR; Smith RL
    Xenobiotica; 1986 May; 16(5):503-9. PubMed ID: 3739370
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.